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Abstract: Background: Heart Failure (HF) and cognitive impairment (CI) represent two high incident 
diseases worldwide, with extremely elevated mortality and morbidity rates. Their prevalence is ex-
pected to further increase in the next years due to the aging population, thus they pose enormous clinical, social and eco-
nomic challenges. Sympathetic nervous system hyperactivity is known to play a pivotal role in HF pathophysiology and 
progression. In fact, increased cardiac and circulating catecholamine levels are responsible for several molecular and 
structural abnormalities with detrimental effects on the failing heart. The poof of this latter concept is represented by the 
clinical success of -Blocker therapy that is able to attenuate HF-related morbidity and mortality. Recently, adrenergic 
system alterations have been implied also in the pathogenesis of CI and dementia opening the window for new fascinating 
and promising therapeutic opportunities.  
Objective: Assess the state of the art on the relationship between cognitive impairment and heart failure. 
Method: In the present manuscript, we propose an updated review of literature and patent on the role of sympathetic 
nervous system derangement in the pathogenesis of HF and CI.  
Conclusion: We have discussed recent findings allowing the identification of new molecular targets that hopefully will 
contribute to the generation of effective therapeutic strategies for HF and dementia. 
In this article, the patents US20100048479, US7060871, WO2006052857, US7351401, US5721243, WO1994009155, 
US5449604, WO1999058981, US5985581, EP2319511, EP2377534, EP2650303, WO2006004939, WO2010132128 and 
EP1779858 are summarized. 
Keywords: -Blocker, cognitive impairment, dementia, GRK2, heart failure, sympathetic nervous system. 
INTRODUCTION 
Epidemiology of Heart Failure and Cognitive Impair-
ment 
 Heart Failure (HF) is an important public health problem 
and its prevalence is expected to progressively increase due 
to population ageing [1]. HF can be defined as a complex 
clinical syndrome in which patients have several symptoms 
and signs resulting from any structural or functional cardiac 
disorder that causes inability of the heart to provide adequate 
blood flow to other organs. Several epidemiological studies 
have investigated incidence and prevalence of HF, frequently 
reporting conflicting results, probably due, at least in part, to 
the different diagnostic criteria adopted. According to a re-
cent review about 37.7 million people are estimated to be  
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living with HF in the world [2]. Data from the American 
Heart Association (AHA) indicate a prevalence of 5.1 mil-
lion people with HF only in the United States [3], with the 
prevalence in African-Americans that is higher than in Cau-
casian [4]. The prevalence of HF reported in ESC guidelines 
is 1-2% in the developed world, increasing to 10% among 
patients 70 years of age or older, while the incidence was 
evaluated as 0.5-1% subjects/year [5]. The Framingham 
Heart Study showed trends toward increasing HF prevalence 
in older people: it was estimated 0.8% at age 50-59 years, 
rising to 6.6% at ages 80 to 89 years, with similar values 
(respectively 0.8% and 7.9%) in women [6]. This trend is 
paralleled by an increase in the rate of hospitalization due to 
HF, which is the major cause of hospitalization in patients 
older than 65 years. In elderly subjects with HF one of the 
most common medical conditions associated is cognitive 
impairment (CI) [7]. Rait et al. have examined the preva-
lence of CI in subjects aged 75 years and over in the UK [8]. 
CI assessed by Mini-Mental State Examination (MMSE) 
showed a prevalence of 18.3% for mild impairment and of 
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3.3% for moderate to severe impairment, with a higher 
prevalence in women. The prevalence of CI in HF patients, 
as well as cardiac dysfunction, increases with aging and its 
incidence varies widely from 25% to 70-80% according to 
presence of comorbidities, methods adopted to assess cogni-
tion and study designs [9-12]. It seems that the different 
cognitive domains (attention, executive function, learning 
and memory, language, visuospatial functioning and psy-
chomotor speed) are affected in patients with HF. Also, the 
severity of cognitive dysfunction is correlated to HF severity 
and several brain changes observed in dementia are also 
found in patients with HF. Among them, increased cortical 
atrophy, cerebral infarcts, white matter changes and meta-
bolic alterations have been identified in HF subjects and 
might contribute to cognitive decline onset and progression. 
Data from recent studies also demonstrate that cognitive 
deficits in HF are, at least in part, reversible. Improved clini-
cal management and close monitoring of cardiovascular 
function might prevent cognitive deterioration in HF pa-
tients, as suggested by studies that have shown improved 
cognitive function in persons with HF as a result of cardiac 
transplantation pacemaker and cardiac assist device implan-
tation and initiation of treatment with ACE inhibitors [13]. In 
this review we aim to explore the relationship between HF 
and dementia, with a particular focus on the possible role of 
the adrenergic system. 
Cardiac Adrenergic System: Anatomy and Physiology 
 The autonomic nervous system (ANS) is the part of the 
nervous system that regulates visceral functions to maintain 
the body homeostasis and to allow reactions and adaptation 
to external and internal stressors. The ANS is divided into 
sympathetic (or adrenergic) nervous system (SNS) and para-
sympathetic (or cholinergic) nervous system. These branches 
have different neurotransmitters that generally exert opposite 
effects on target tissue through the activation of adrenergic 
and cholinergic receptors. SNS exerts relevant cardiovascu-
lar effects, such as increase heart rate and contractility, low-
ering venous capacitance and vasoconstriction. Instead the 
parasympathetic nervous system has minimal effects on con-
tractility and acts mainly by inducing bradycardia through 
vagal impulses [14]. 
 Cardiac anatomic distribution of ANS fibers is different 
for the two branches: adrenergic nerve travel in the epicar-
dium, run along coronary arteries and reach mainly the ven-
tricular myocardium, while cholinergic nerve fibers travel 
with vagus nerve in the subendocardium and reach primarily 
the atria and at a lesser extent the ventricular myocardium. 
Accordingly, the heart rate is under the control of both parts 
of the ANS, whereas myocardial contractility is regulated 
almost exclusively by the SNS [15].  
 The two branches of the ANS are composed of afferent, 
efferent and interneuronal fibers, involved in cardio-cardiac 
reflexes. Afferent fibers run to the central nervous system via 
the autonomic nerves, while efferent fibers reach target or-
gans with autonomic or somatic nerves. The principal reflex 
responses derive from the aortic arch, the carotid barorecep-
tors, the cardiopulmonary baroreceptors, the cardiovascular 
low-threshold polymodal receptors and the peripheral 
chemoreceptors [15].  
 The cardiovascular effect of SNS is mediated by the re-
lease of two catecholamines (CAs): norepinephrine (NE or 
noradrenaline) and epinephrine (EPI or adrenaline). CAs act 
through several mechanisms: NE, released by cardiac sym-
pathetic nerve terminals (only a minimal rate derived from 
adrenal medulla), increases heart rate, reduces atrioventricu-
lar conduction and increases contractile strength and blood 
pressure; EPI, released into the circulation by the adrenal 
medulla, has effects on the myocardium and peripheral ves-
sels; finally, both CAs can be locally released by various 
peripheral adrenergic nervous systems via autocrine/ 
paracrine and are located in blood vessels and in cardiac 
myocytes themselves [15, 16]. The parasympathetic activity 
is mediated by acetylcholine, that activating specific recep-
tors, decreases sinoatrial node depolarization rate and atriov-
entricular node conduction velocity, thus resulting in reduced 
heart rate with minimal or no effect on cardiac contractility. 
 Alterations in autonomic function are involved in the 
pathogenesis of several cardiovascular diseases, including 
HF, hypertension, cardiac arrhythmias, myocardial ischemia, 
and sudden cardiac death [17]. Importantly, SNS hyperactiv-
ity is one of the most important neuro-hormonal mechanisms 
underlying heart failure pathogenesis and progression [18]. 
Adrenoceptors in the Cardiovascular System 
 The adrenergic receptors belong to the G proteins- cou-
pled receptors (GPCRs) superfamily consisting of a seven-
transmembrane-spanning receptor domain and an intracellu-
lar heterotrimeric G-protein complex (G) domain. In the 
inactive form the G protein binds the nucleotide GDP ensur-
ing the subunit  attached to the complex. When the receptor 
is activated by agonist, the subunits  remain anchored to 
plasma membrane, while the subunit  hydrolyzes GTP and 
dissociates from the complex. The  subunit can stimulate 
(Gs) or inhibit (Gi) adenylate cyclase, or activate phos-
pholipase C (Gq). The adrenoceptors are classified in  and 
 receptors based on their responses to drugs, the endoge-
nous ligands, their distribution in tissues and structural char-
acteristics [19]. The -adrenergic receptors (AR) are di-
vided into three 1-receptors (1A, 1B, 1D) and three 2-
receptor (2A, 2B and 2C). The 1-AR recognizes EPI as the 
main agonist and couples to the Gq protein, thus activating 
phospholipase C. Phospholipase C cleaves phosphatidyli-
nositol 4, 5 bisphosphate, which in turn increases inositol 
triphosphate and diacylglycerol. Inositol triphosphate inter-
acts with calcium channels of endoplasmic and sarcoplasmic 
reticulum increasing intracellular calcium store, whereas 
diacylglycerol activates protein kinase C and transient recep-
tor potential channels. 1-ARs are mainly localized in vascu-
lar smooth muscle and, following activation, induce blood 
vessel vasoconstriction (i.e. aorta, pulmonary arteries, mes-
enteric vessels). 2- AR is a presynaptic receptor placed in 
the nerve fiber endings and coupled to the Gi protein. Its 
activation causes a negative feedback on NE release from the 
presynaptic neurons. Furthermore, 2-AR activation causes a 
decrease in cAMP activity resulting in smooth muscle con-
traction. These receptors are mainly localized in central nerv-
ous system and in vascular pre-junctional terminals. The 
ARs include three subtypes: 1, 2, 3. All signal through 
Gs proteins, although 2AR also couples to Gi. The human 
heart contains all three AR subtypes, with 1AR represent-
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ing 75-80% of all cardiac adrenergic receptors and with ex-
pression levels that are ~4 times higher compared to 2ARs. 
2 ARs and 3ARs receptors are less represented in the heart 
(15-18% and 2-3% of total cardiac ARs, respectively).  
ARs are activated following binding by sympathetic neuro-
transmitters (NE and EPI) and, upon activation, they increase 
heart rate (chronotropy), contraction force (inotropy) and 
hearth relaxation (lusotropy) [20]. Gs protein signaling 
stimulates the adenylate cyclase, causing an increase in 
AMPc synthesis and activation of Protein Kinase A (PKA). 
This latter kinase phosphorylates several substrates inducing 
an elevation in intracellular calcium that is the most impor-
tant regulator of cardiac contractility. PKA can phosphory-
late 2AR reducing receptor affinity for Gs and increasing its 
affinity for Gi. The activation of 2AR Gi-dependent signal-
ing triggers a pro-survival, pro-angiogenic and anti-apoptotic 
pathway, while the stimulation of 1AR acts via Gs and has a 
pro-apoptotic effect in cardiomyocyte [21, 22]. Finally, 
3AR has a marginal role in physiological conditions, but it 
is upregulated in HF. Its activation seems to produce a nega-
tive inotropic effect, balancing 1AR and 2AR signaling, 
through a pathway mediated by Gi/o and endothelial type-3 
NO synthase [23]. Importantly, alteration in cardiac AR 
signaling and function are of great relevance in the patho-
genesis of cardiovascular diseases, including HF [24]. 
Adrenoceptors in Brain 
 The major source of NE in brain is the locus coeruleus 
(LC), located in the dorsal pontine tegmentum and connected 
to several brain regions including brainstem, cerebellum and 
neocortex. The LC plays an important role in the regulation 
of vigilance and sleep-wake cycles as well as in attention, 
synaptic plasticity and memory formation and retrieval [25].  
 The NE exerts its effects in the CNS through three 
classes of adrenergic receptors: 1AR, 2AR and AR, the 
latter divided into the 1, 2 and 3 subtypes. While the 
1AR and AR are post-synaptic receptors, the 2AR is pre-
synaptic and, when stimulated, it inhibits further NE release 
in the synaptic cleft [26, 27].  
 Several studies have investigated the role of AR in the 
CNS and, in particular, in the regulation of cognitive func-
tions. It seems that activation of the 1AR improves learning 
and the use of 1AR antagonists like prazosin decrease spatial 
learning [28, 29]. Genetic studies have also shown that both 
1A-AR and 1B-AR knockout mice exhibit impaired cognitive 
functions, especially in spatial learning and memory [30]. As 
for the 2AR, it has been reported that antagonism of these 
receptors improves cognition. In particular, preclinical studies 
with the 2AR blocker yohimbine have demonstrated benefi-
cial effects on spatial memory assessed by Morris water maze 
test in rodents [31]; other researchers have demonstrated that 
dexefaroxan, another 2AR antagonist, is able to ameliorate 
learning and memory in treated mice [28]. On the contrary, 
2AR agonist clonidine impairs fear memory reconsolidation 
but, interestingly, it improves working memory in the prefron-
tal cortex [32]. Working memory deficits have also been ob-
served in knockout mice for 2A-AR [33]. 
 Also the AR exert important functions is the CNS, as 
demonstrated by several pharmacological studies. The AR 
agonist isoproterenol has been shown to improve memory 
consolidation and long term potentiation in the mouse hippo-
campus [34]; intra-amygdalar injection of the 2AR agonist 
clenbuterol enhances retention of the inhibitory avoidance in 
mice [35]. Conversely, recent data indicate that the AR 
blocker propranolol is able to improve performance during 
cognitive flexibility tasks in rodent [36] while xamoterol, a 
partial 1AR agonist, impairs hippocampus-dependent emo-
tional memory retrieval in mice [37]. Mirbolooki et al. have 
demonstrated that intracranial administration of 3AR an-
tagonists induces amnesia in chicks, while memory loss is 
rescued by 3AR antagonists [38]. 
Regulatory Mechanisms of Adrenoceptor Signaling and 
Function 
 Adrenergic receptor signaling is highly regulated, under-
going processes known as desensitization and down-
regulation. In this scenario, a prominent role is played by the 
family of G protein-coupled receptor kinases (GRKs), and in 
particular by GRK2 that represents the predominant isoform 
in the heart. GRK2 is a serine/threonine cytosolic kinase and, 
within its well-conserved structure, contains a central cata-
lytic domain, an amino-terminal domain and a carboxyl-
terminal domain that includes specific regulatory sites [39]. 
GRK2 is primarily a cytosolic protein, but once GPCRs, 
including cardiac ARs, are activated by agonists, it translo-
cates to the plasma membrane where it is able to come in 
contact and phosphorylate agonist-occupied ARs, initiating 
the processes of receptor desensitization [40]. It is well 
known that in order to move to the plasma membrane GRK2 
binds the G subunits of the heterotrimeric G-proteins 
through binding sites within its carboxyl-terminal domain. 
Following receptor phosphorylation by GRK2, -arrestins 
bind this complex preventing further G-protein-mediated 
signaling [41]. Thus, -arrestins have been originally de-
scribed as a terminator of GRCR signaling. More recently, it 
has been described that -arrestins are able to activate 
through scaffolding functions an alternative signal, known as 
G protein independent signaling [42, 43]. Under physiologi-
cal conditions, signal through ARs is the result of receptor 
activation by agonists and receptor phosphorylation by 
GRK2 which initiates processes of receptor desensitiza-
tion/downregulation. However, there are several demonstra-
tions available of the therapeutic effects of GRK2 inhibition 
in the heart via the peptide ARKct, which competes with 
endogenous GRK2 for G binding at the plasma membrane 
[44-46]. Moreover, preclinical studies have shown that long-
term administration of AR agonists increases cardiac GRK2 
activity, while -blocker decreases GRK2 levels in the heart 
[39]. Thus, it is nowadays widely accepted that up-regulation 
of cardiac GRK2 levels/activity, despite protective in the 
short term with the attempt to defend the heart from the toxic 
effects of excessive AR activation, it becomes maladaptive 
over time blunting AR signaling that become unresponsive 
to SNS activation.  
Assessment of SNS Hyperactivity 
 The sympathetic and parasympathetic nervous system 
regulates several physiological functions, including cardio-
vascular (blood pressure and heart rate modulation), respira-
tory, gastrointestinal and urinary ones. 
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 The dysfunction of the autonomic nervous system can be 
evaluated by a number of feasible tests, especially aiming at 
the assessment of cardiovascular autonomic modulation [47].  
Heart Rate Interval Variability 
 It is calculated on a continuous electrocardiogram (ECG), 
recorded for 5 minutes while the patient is resting supine. 
Both time-domain indexes and frequency-domain indexes 
are calculated. Time-domain indexes are based on a statisti-
cal calculation of consecutive R-R intervals, while fre-
quency-domain indexes derive from a spectral method that 
analyses the fluctuations in the frequency domain. A specific 
algorithm is used to convert R-R intervals on ECG in spec-
tral density, and the ratio between low frequency/high fre-
quency bands represents a marker of sympathovagal balance 
[48]. 
Ewing’s Battery Tests 
 This battery is composed of five cardiovascular reflex 
tests originally developed to evaluate autonomic function in 
diabetic patients [47]. They involve the recording of con-
tinuous ECG and include the following: 1) Valsalva ratio, 
which is calculated dividing the maximal R-R interval by the 
minimal R-R interval during the Valsalva maneuver; 2) 
Heart rate response to standing, calculated by the 30:15 ratio. 
The ratio is the maximum R-R interval at the 30th beat after 
standing divided by the minimum R-R interval at the 15th 
beat after standing. 3) R-R interval variation (RRIV) during 
rest and deep breathing which is calculated while the patient 
performs forced deep breaths at a rate of 6 per minute. The 
mean R-R is calculated as the mean value of the longest and 
shortest R-R and the average R-R is calculated as the differ-
ence between the longest and shortest R-R intervals. The 
RRIV is the ratio between mean/average R-R. 4) Blood pres-
sure variation (BP), which can be measured according to 
several methods. Classically, orthostatic hypotension is 
evaluated by monitoring BP in supine position after 10 min-
utes of rest and then after 3 minutes of active standing posi-
tion. However, BP variation can be evaluated during Val-
salva maneuver, as the difference between the peak systolic 
BP during the maneuver and the mean systolic BP prior to 
the maneuver, or during isometric exercise, calculated as 
difference between the mean diastolic BP prior to sitting 
position and just before the end of sitting exercise, or after a 
cold presser test, as diastolic BP variation after the partici-
pant submerges his left hand in cold water at 4°C. According 
to the Ewing’s classification and depending on how many 
tests are normal, borderline or abnormal, cardiovascular 
autonomic function can be classified as normal, early im-
paired, definitely impaired, severely impaired or atypical, 
with the heart rate tests providing information on the para-
sympathetic function and the BP tests better evaluating sym-
pathetic function [49]. 
Baroreflex (BR) Estimation 
 As BR is the mechanism responsible for BP and HR con-
trol, BR estimation consists of simultaneous ECG recording 
and BP assessment. Indeed, The BR provides a rapid nega-
tive feedback loop when abrupt changes in BP cause a 
modulation of the HR in order to restore the BP, as a result 
of sympathovagal activation [50].  
Carotid Sinus (CS) Massage 
 After 5 seconds of CS massage, a fall in HR can be no-
ticed and after 20 seconds, a fall in BP is usually found. This 
response is a measure of CS reflex sensitivity but should be 
avoided in patients with cerebrovascular events or recent 
myocardial infarction [51]. 
Plasma Epinephrine and Norepinephrine Measurement 
 The levels of plasma cathecolamines should be evaluated 
after both 30 minutes in resting supine position and after 5 
minutes of orthostatic standing. Blood samples should be 
kept in ice and processed within 1 hour of collection [47]. 
123I-MIBG Scintigraphy 
 The iodine-123 metaiodobenzylguanidine (123I-MIBG) 
imaging is a noninvasive scintigraphy assessing adrenergic 
neuronal efferent in the heart, as the MIBG is a noradrena-
line analogue competing for the noradrenaline transporter. A 
reduced MIBG uptake has been correlated to sympathetic 
dysfunction in heart failure and diabetic neuropathy [52]. 
Interestingly, myocardial MIBG scintigraphy helps to differ-
entiate between Parkinson’s disease and other parkinsonian 
syndromes, as well as to differentiate between dementia with 
Lewy body and AD [53]. 
Heart Failure Pathophysiology 
 Any cardiac structural or functional disorder, that com-
promises ventricular filling or emptying, may lead to the 
development of HF. About half of patients with HF have a 
reduction of the ejection fraction. In these patients, the most 
frequent cause of systolic HF is coronary artery disease, of-
ten associated with the presence of diabetes and hyperten-
sion. HF with preserved ejection fraction is a growing prob-
lem, but is associated with a better prognosis compared to 
heart failure with impaired systolic function. It seems to be 
more frequent in older adults and women, and is often sec-
ondary to arterial hypertension and left ventricular hypertro-
phy, rather than coronary artery disease [5, 14, 15]. 
 The failing heart activates several compensatory mecha-
nisms, such as the Frank-Starling mechanism, ventricular 
remodeling and neurohormonal activation, in order to main-
tain adequate tissue perfusion. In particular, Frank-Starling 
mechanism establishes that cardiac muscle contraction in-
creases in response to a rise in the volume of blood filling 
the heart. Accordingly, left ventricular stroke volume is di-
rectly proportional to the amount of blood present in the ven-
tricle at the end of diastole. Augmentation in ventricular pre-
load causes an elongation of the sarcomere, and so an imme-
diate increase in the force of contraction. This phenomenon 
appears to be due mainly to a greater cardiomyocyte calcium 
sensitivity elicitated by stretching. 
 Cardiac remodeling consists of a series of structural and 
functional alterations, in response to pressure overload, vol-
ume overload or cellular damage. Several alterations are 
reported at cellular level, such as cardiomyocytes hypertro-
phy, necrosis and apoptosis, accumulation of pro-
inflammatory mediators, fibroblast proliferation and ex-
tracellular matrix rearrangement. Macroscopically, it is char-
acterized by the presence of ventricular hypertrophy and 
dilatation due to cardiomyocyte elongation and reorganiza-
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tion. These changes lead to a variation in ventricular geome-
try in the attempt to maintain an adequate stroke volume and 
cardiac output in response to the reduced ejection fraction. 
Cardiac remodeling process is progressive and in the long 
term harmful: it increases myocardial oxygen demand and 
reduce myocardial contractility, leading to less effective 
pumping. 
 Neurohumoral activation includes the renin–angiotensin–
aldosterone system (RAAS) and hyperactivation of the sym-
pathetic nervous system. RAAS is overactive in HF and con-
tributes to disease progression through impairment of pres-
sure stability and fluid volume homeostasis. RAAS, through 
the activation of angiotensin II receptor type 1 (AT1), causes 
systemic and renal vasoconstriction, renal blood flow reduc-
tion and an increase in glomerular filtration and proximal 
sodium and fluid reabsorption. In addition, AT1 activation 
induces oxidative stress, inflammatory cytokines production, 
fibroblasts activation, vascular smooth muscle growth and 
endothelial dysfunction [54]. These effects lead to progres-
sive renal and heart injury. AT1 activation also stimulates 
aldosterone secretion, resulting in sodium and water reten-
tion [55]. Aldosterone receptors are located in several tissues 
(i.e. heart, blood vessels and brain) and, together with angio-
tensin, contribute to the development of cardiac fibrosis and 
remodeling [56, 57]. Due to its central role in HF patho-
physiology, RAAS is currently an important pharmacologi-
cal target in HF management. Other neurohormones are hy-
perctivated in HF, such as atrial natriuretic peptide (ANP) 
and brain natriuretic peptide (BNP), released in response to 
atrial and ventricular stretching, and C-type natriuretic pep-
tide (CNP) found predominantly in the central nervous sys-
tem. They determine vasodilation, increase sodium and wa-
ter secretion, and also inhibit the release of renin, aldosterone 
and vasopressin [58].  
 Although all these mechanisms are initially beneficial, 
attempting to support cardiac function, overtime they be-
come maladaptive, leading to reduction of cardiac contractil-
ity and facilitating HF progression [5]. 
Role of SNS Hyperactivity in HF (Regulation of SNS Ac-
tivity and Effects of SNS Hyperactivity on Cardiac 
Adrenoceptors) 
 SNS activation is one of the first adaptive responses to 
reduced cardiac function, primarily resulting from decreased 
blood pressure. Sympathetic hyperactivation is characterized 
by increased NE release and decreased NE reuptake from 
sympathetic nerve endings, resulting in increased NE spill-
over [14, 15]. Physiologically, SNS activation is under the 
control of pressure-sensitive receptors, known as barorecep-
tors that can be divided into two categories based on the type 
of blood vessel in which they are located: high-pressure 
baroreceptors placed in the carotid sinus and aortic arch, and 
low-pressure baroreceptors, located in the right atrium and in 
the wall of major veins. These receptors are involved in the 
control of SNS activity, specifically activating a negative-
feedback. Their actions are opposite to activation of periph-
eral chemoreceptors that stimulate SNS. During HF, this 
equilibrium is shifted towards increased activation of SNS, 
with decreased sympatho-inhibitory and increased sym-
patho-excitatory reflexes, leading to altered heart rate vari-
ability, increased peripheral resistance, blood pressure, ven-
tricular contractility and heart rate, in order to maintain the 
cardiac output. Recently, a new molecular mechanism con-
trolling SNS outflow in HF has been described [59, 60]. 
Briefly, GRK2 up-regulation in the adrenal medullary chro-
maffin cells leads to down-regulation of the sympatho-
inhibitory 2AR. The loss of this negative feedback to 
catecholamine release results in uncontrolled NE and EPI 
production, with a relevant role both under physiological 
conditions and in the patho-physiology of sympathetic hy-
peractivation observed in HF [60, 61]. Importantly, this 
mechanism seems to be involved also in the increased NE 
release from cardiac nerve endings [62]. In vivo GRK2 inhi-
bition in the chromaffin cells of HF rats results in reduced 
SNS activity and ameliorated cardiac function. Therapeutic 
modalities known to positively modulate sympathetic activ-
ity in HF are able to reduce circulating catecholamine via 
restoration of adrenal 2AR signaling [63, 64]. 
 Similarly to other neurohormonal systems, also adrener-
gic hyperactivity exerts detrimental effects on cardiac func-
tion and structure in the long-term [14, 15]. In fact, circulat-
ing catecholamine levels, as well as other parameter of SNS 
activity, are directly correlated with HF severity and mortal-
ity, suggesting plasma NE as a guide to prognosis in patients 
with congestive HF [58]. As already mentioned, sustained 
SNS activation causes cardiac AR desensitization and 
downregulation via increased GRK2 activity, resulting in 
impaired chronotropic and inotropic responses [65]. The 
1AR is primarily involved in this mechanism, leading to 
cardiomyocyte apoptosis, necrosis and hypertrophy and in-
creased oxidative stress [66, 67]. Differently, 2AR is exclu-
sively desensitized in HF, suggesting that this receptor may 
be relevant for the inotropic support of the failing heart HF. 
In addition, 2AR exerts anti-apoptotic effects in contrast to 
the pro-apoptotic action of 1AR stimulation. Of note, in 
vivo gene therapy experiments, aiming at cardiac GRK2 in-
hibition, resulted in improved cardiac function, ameliorated 
1AR and 2AR, activation of alternative receptors signaling 
and reduced SNS outflow [68-74].  
 The pivotal role of GRK2-mediated AR down-
regulation in HF pathophysiology prompted researchers to 
investigate a potential role of this kinase as a biomarker in 
patients with chronic HF [64]. Importantly, cardiac GRK2 
levels depend on the degree of AR stimulation by CAs, thus 
reflecting the status of adrenergic activation of the failing 
heart [65]. Cardiac GRK2 levels are mirrored by circulating 
lymphocytes, tracking with the degree of HF severity and 
cardiac dysfunction [75]. It has been shown that lymphocyte 
GRK2 protein levels independently predict prognosis among 
patients with HF [76] and blood GRK2 levels can change in 
response to specific HF therapies [77, 78]. 
-Blockers in HF 
 Over the past three decades, HF therapeutic armamen-
tarium has been enriched with several drugs that have been 
shown not only to curb symptoms in these patients, but also 
to significantly reduce HF-related mortality [5]. Among 
these new therapeutic opportunities, the introduction of -
blocker represents a milestone in HF therapy. The success of 
-adrenergic blocking agents use in patients with mild-to-
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moderate chronic heart failure has been widely demonstrated 
in clinical trials over the past 20 years and their use is widely 
recommended in guidelines [5]. -Blockers are usually clas-
sified into three generations: a) the first generation includes 
blockers that unselectively bind both 1 and 2AR subtypes, 
examples of this class are propanol and timolol; b) the sec-
ond generation, includes -blockers with higher affinity for 
the 1AR than for the 2AR, examples of this class are me-
toprolol and bisoprolol); and c) the third generation, which 
includes both subtype-selective (nebivolol) or subtype-
nonselective (carvedilol) blockers, that can also block 
1ARs, thereby causing peripheral vasodilation (i.e. bucin-
dolol, carvedilol). Nebivolol can also induce nitric oxide 
production. All -adrenergic antagonists exert negative 
chronotropic and inotropic effects, but 1AR-selective 
agents less frequently cause bronchoconstriction and vaso-
constriction. The reduction in cardiac inotropism and heart 
rate results in decreased oxygen/energy demand of the fail-
ing heart, thus, improving cardiac function in the long-term. 
However, there are several other mechanisms reported for 
the beneficial effects of -blocker therapy in HF, including: 
reverse ventricular remodeling, reduced risk of arrhythmias, 
increased cardiac angiogenesis and coronary blood flow 
[79], protection of the heart from the cardiotoxic effects of 
catecholamine, restoration of cardiac AR signaling [80], 
improved cardiac inotropic reserve, reduction of SNS hyper-
activity [81].  
Cognitive Impairment Pathophysiology 
 Alzheimer’s disease is a neurodegenerative condition and 
the most common cause of dementia, accounting for 60-80% 
of cases. It is clinically characterized by a progressive de-
cline in memory, language, problem solving abilities and 
deficits in other cognitive domains that ultimately result in 
the loss of the patients’ ability to perform activities of every-
day life.  
 Evidence from clinical and preclinical studies conducted in 
the last decades have shown that the brain changes associated 
with AD begin 20 or more years before the disease manifests 
clinically with cognitive symptoms. This time from the initial 
brain changes to the symptoms onset has been defined as the 
“AD continuum” and, also thanks to this new concept, the 
diagnostic criteria for AD have been revisited in 2011 by the 
National Institute on Aging (NIA) and the Alzheimer’s Asso-
ciation [82]. While the 1984 diagnostic criteria were based on 
the presence of memory loss and cognitive deficits for the AD 
diagnosis to be made, the 2011 criteria identify three stages of 
AD (preclinical, mild cognitive impairment and dementia), 
with the first occurring before symptoms development, and 
introduce biomarkers tests. These criteria and guidelines iden-
tify two biomarker categories: a) markers of beta-amyloid 
accumulation in the brain and b) markers of neurodegenera-
tion. Indeed, AD is characterized, from the neuropathological 
point of view, by the formation of extracellular amyloid  
(A) plaques and intraneuronal deposits of neurofibrillary 
tangles (NFTs). NFTs are helical filaments constituted by hy-
perphosphorylated tau protein, while A plaques are formed 
of aggregated amyloid  peptide [83]. The NFT in AD are 
found in the amygdala, hippocampus and temporal association 
cortex while A plaques are distributed throughout the asso-
ciation neocortex and in the striatum. Apart from these two 
well-known pathophysiological mechanisms, other factors 
contribute to AD onset and progression. Neuroinflammation 
(the inflammatory response in the central nervous system sec-
ondary to neuronal insult) is one of these and its cellular play-
ers are microglia and astrocytes. Despite being described as 
protective in the early phases and aimed at the removal of 
toxic A, in the long term neuroinflammation results detri-
mental, contributing to brain damage with the release of cyto-
kines and neurotoxic agents from activated glial cells [84]. In 
addition to that, vascular pathological alterations have an im-
portant role in AD pathogenesis, as demonstrated by several 
studies [85]. Vascular injury induces toxic accumulation of A 
and capillary hypoperfusion, leading to early neuronal dys-
function while A accumulation in the perivascular region 
leads to cerebral amyloid angiopathy; moreover, cardiovascu-
lar diseases are an important causal or contributing factor in 
AD, with hypertension regarded as the most powerful vascular 
risk factor for AD [86]. Additionally, it is well established that 
both early-onset and late-onset AD have a genetic component. 
In the late-onset form, apolipoprotein E (APOE) has been es-
tablished as the most important susceptibility gene; recent 
evidence from genome-wide association studies (GWAS) has 
identified other new loci for AD risk but all their effect is 
much smaller compared to those of APOE [87, 88].  
 From the therapeutic point of view, drug development for 
AD has proven to be very difficult, with only four drugs cur-
rently approved for the treatment of AD including three cho-
linesterase inhibitors (donepezil, rivastigmine, galantamine) 
and an N-methyl-D-aspartate (NMDA) receptor AD antago-
nist (memantine). In the decade 2002-2012, over 400 inter-
ventional trials have been conducted in AD, with an overall 
success rate of 0.4% (99.6% failure), thus there is an urgent 
need for new therapies in AD [89]. Moreover, along with the 
search for therapies that can modify the course of AD, there 
is a need to identify reliable biomarkers to help in diagnosis 
and monitoring progression, with neuroimaging markers 
being among the most valuable tools for this purpose. In-
deed, structural brain MRI and fluoro-deoxy-D-glucose 
(FDG)-PET already have a role in evaluating brain atrophy 
and metabolism respectively but, in recent years, other PET 
tracer have been developed to specifically assess AD neuro-
pathology in vivo; among them, amyloid imaging, microglial 
activation and neuroinflammation, cholinergic pathways, 
and, more recently, imaging tau and neurofibrillary tangles 
have an invaluable role [90-96].  
Potential Involvement of SNS Dysfunction on Cognitive 
Function: The New Adrenergic Hypothesis? (Should this 
question mark come?) 
 Alterations in autonomic function are found in AD pa-
tients and they are due, at least in part, to the deficit in cen-
tral cholinergic function observed in these patients. Several 
recent lines of evidence indicate a potential involvement of 
AR system also in AD pathogenesis, with interesting impli-
cations on the clinical management of subjects with CI. This 
is relevant since the current therapeutic armamentarium 
available to treat dementia, only allows symptomatic im-
provement without any effect on disease progression. The 
central noradrenergic system undergoes extensive modifica-
tions in the course of AD.  
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 Different lines of evidence have shown that in AD there 
is a significant decrease in the total concentration of ARs in 
many brain regions. Importantly, 1ARs concentration is 
significantly reduced in the hippocampus while 2ARs are 
decreased in the thalamus, cerebellum and in the nucleus 
basal of Meynert, highlighting many ARs changes in AD 
dementia [97]. Importantly 2ARs stimulation by NE causes 
increase of cAMP that results in an overexpression in APP 
by enhancing  secretase activity [98]. 
 Moreover, A is implicated in 2 AR internalization and 
degradation mediated by phosphorylation of GRKs and ar-
restins resulting in a decrease in noradrenergic activity [99]. 
 Indeed, LC degeneration occurs early in AD pathogene-
sis and reduction in cortical NE concentration and in NE 
transporter correlate with the severity of CI [100-102]. 
 LC degeneration is caused by the early occurrence of 
abnormal hyperphosphorilated tau proteins in a few neurons 
of the LC that can aggregate into neurofibrillary tangles. 
Other studies indicate that NE is increased in the cerebrospi-
nal fluid of AD patients [103], probably as a compensatory 
effects occurring in the remaining noradrenergic brain areas 
[104]. Importantly, also ARs seem to play a role in CI, with 
implications not only on amyloid production and precipita-
tion, but also in amyloid-dependent neurotoxicity [105-107]. 
These observations are supported by recent evidence indicat-
ing a possible role of -blocker therapy in AD onset and 
progression [27]. Finally, it is important to underline that 
post-receptor components of AR system, and in particular 
GRK2, might be involved in AD pathogenesis. Lymphocyte 
GRK2 levels are increased in patients with AD, tracking the 
degree of CI [108]. Deeper knowledge on the role of the 
adrenergic system in AD pathogenesis is of great clinical 
interest for the development of novel prognostic and thera-
peutic strategies. 
SNS Dysfunction as a Link between Heart Failure and 
Cognitive Decline 
 Both HF and AD represent growing healthcare and social 
problems, especially in the elderly population; they often 
occur together, increasing the cost of healthcare. Several 
non-cardiac conditions might indeed impact on HF-related 
mortality and CI is among those [109-110]. This underlines 
the importance of investigating the relationship between 
these conditions, and SNS dysfunction might play a role in 
that. 
 It is known that appropriate treatment of cardiovascular 
conditions can reduce the prevalence of AD and that heart 
disease and AD share similar risk factors and genetic suscep-
tibility genes, such as ApoE polymorphisms. Moreover, the 
relationship between HF and cognitive impairment is further 
confirmed by the fact that the “cardiogenic dementia” was 
identified in the 1970’s and since then several studies have 
shown that HF contributes to cognitive decline and that its 
severity correlates with cognitive performance. One of the 
factors possibly linking the two conditions is the inadequate 
blood supply due to reduced cardiac output in HF, as it has 
been confirmed by data indicating that reduced left ventricu-
lar ejection fraction is associated with impaired cognition 
and that low cardiac index is associated with low brain vol-
ume [111]. Moreover, it has been demonstrated that patients 
with HF present with more white matter hyperintensities, 
lacunar infarcts and medial temporal lobe atrophy, compared 
to healthy controls and that patients with AD have a reduced 
regional and total cerebral blood flow resulting in brain hy-
poperfusion, compared to cognitively normal controls [112, 
113]. A chronic reduction in cerebral blood flow might result 
in cellular hypoxemia and acidosis, followed by oxidative 
stress, ultimately aggravating both A and tau pathologies. 
 As discussed above, impaired cardiac function activates 
neurohormonal systems, as the SNS and the renin-
angiotensin-aldosterone system, further contributing to HF 
progression. Altered neurohormonal signals also activate the 
CNS, which in turns regulates cardiac function; however, the 
exact mechanisms of this regulation are still unknown. Pre-
clinical evidence indicates that brain administration of -
blockers in an animal model of myocardial ischemia reduced 
mortality more effectively than peripheral administration 
[46].  
 In addition to that, several studies indicate that an im-
pairment of autonomic function is present both in HF and 
AD and more importantly, modifications of the cardiac sym-
pathovagal balance towards a higher sympathetic and lower 
parasympathetic modulation are highly prevalent in the eld-
erly and might contribute to disrupted homeostatic adaptive 
capacity in both conditions [114]. 
 Thus, it is likely that the relationship between HF and 
AD might reflect neurohormonal activation and its systemic 
consequences, rather than perfusion alone. 
 In summary, data from the studies reviewed here globally 
indicate that: 
• HF and AD represent growing healthcare problems 
in the elderly population that can often occur simul-
taneously 
• Improved medical treatment of cardiovascular con-
ditions can reduce the prevalence of AD 
• HF patients show brain abnormalities that are ob-
served in AD patients (white matter hyperintiensi-
ties, regional atrophy) 
• AD patients present with reduced cerebral blood 
flow resulting in hypoperfusion 
• Altered neurohormonal signals (including the 
adrenergic system) activate the CNS, which in turns 
regulates cardiac function  
• an impairment of autonomic function is present 
both in HF and AD and might be a link between the 
two pathologies 
CURRENT & FUTURE DEVELOPMENTS 
 Given the enormous impact of both HF and AD on eld-
erly health status, it is not surprising that several studies are 
ongoing, in the search for appropriate and effective treat-
ments for both conditions; moreover, increasing interest is 
growing in understanding the relationship between cardio-
vascular disease and cognitive impairment. In the present 
manuscript, we have reviewed how SNS dysfunction might 
be a link between heart failure and neurodegeneration.  
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 Recently, patents have been developed proposing AR 
modulation as a target for both conditions [115], and other 
AR targeted-drugs are being developed in pharmacological 
research [116]. New compounds modulating guanilate cy-
clase have been recently patented as a treatment for HF [117] 
and polymorphisms and haplotypes of the alpha2c AR gene 
are being investigated as a risk factor for HF [118]. In cogni-
tive impairment, few compounds have been patented in the 
last few years for the treatment of this condition [119, 120], 
thus more research studies need to be undertaken, aiming at 
the discovery of effective therapeutic tools.  
CONFLICT OF INTEREST  
 The authors confirm that this article has no conflict of 
interest. 
ACKNOWLEDGEMENTS  
 Declared none. 
REFERENCES  
[1] Roger VL. Epidemiology of heart failure. Circ Res 2013; 113(6): 
646-59. 
[2] Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart 
failure. Nat Rev Cardiol 2016; Doi:10.1038/nrcardio.2016.25. 
[Epub ahead of print] 
[3] Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden 
WB, et al. Heart disease and stroke statistics--2013 update: A re-
port from the American heart association. Circulation 2013; 127(1): 
e6-e245. 
[4] Bahrami H, Kronmal R, Bluemke DA, Olson J, Shea S, Liu K,      
et al. Differences in the incidence of congestive heart failure by 
ethnicity: The multi-ethnic study of atherosclerosis. Arch Intern 
Med 2008; 168(19): 2138-45. 
[5] McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, 
Dickstein K, et al. ESC Guidelines for the diagnosis and treatment 
of acute and chronic heart failure 2012: The task force for the diag-
nosis and treatment of acute and chronic heart failure 2012 of the 
european society of cardiology. Developed in collaboration with 
the heart failure association (HFA) of the ESC. Eur Heart J 2012; 
33(14): 1787-847. 
[6] Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of 
heart failure: The framingham study. J Am Coll Cardiol 1993; 
22(4s1): A6-13. 
[7] Leto L, Feola M. Cognitive impairment in heart failure patients. J 
Geriatric Cardiol 2014; 11(4): 316-28. 
[8] Rait G, Fletcher A, Smeeth L, Brayne C, Stirling S, Nunes M, et al. 
Prevalence of cognitive impairment: Results from the MRC trial of 
assessment and management of older people in the community. 
Age Ageing 2005; 34(3): 242-8. 
[9] Zuccalà G, Marzetti E, Cesari M, Lo Monaco MR, Antonica L, 
Cocchi A, et al. Correlates of cognitive impairment among patients 
with heart failure: Results of a multicenter survey. Am J Med 2005; 
118(5): 496-502. 
[10] Rengo F, Leosco D, Iacovoni A, Rengo G, Golino L, Borgia F,     
et al. Epidemiology and risk factors for heart failure in the elderly. 
Ital Heart J 2004; 5 Suppl 10: 9S-16S.  
[11] Harkness K, Demers C, Heckman GA, McKelvie RS. Screening for 
cognitive deficits using the Montreal cognitive assessment tool in 
outpatients’  65 years of age with heart failure. Am J Cardiol 
2011; 107(8): 1203-7. 
[12] Davis KK, Mintzer M, Himmelfarb CR, Hayat MJ, Rotman S, 
Allen J. Targeted intervention improves knowledge but not self-
care or readmissions in heart failure patients with mild cognitive 
impairment. Eur J Heart Fail 2012; 14(9): 1041-9. 
[13] Galioto R, Fedor AF, Gunstad J. Possible neurocognitive benefits 
of exercise in persons with heart failure. Eur Rev Aging Phys Act 
2015; 12:6. 
[14] Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louri-
das G, Butler J. The sympathetic nervous system in heart failure 
physiology, pathophysiology, and clinical implications. J Am Coll 
Cardiol 2009; 54(19): 1747-62. 
[15] Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system 
in heart failure: Pathophysiology and therapy. Circ Res 2013; 
113(6): 739-53. 
[16] Lymperopoulos A, Rengo G, Koch WJ. Adrenal adrenoceptors in 
heart failure: Fine-tuning cardiac stimulation. Trends Mol Med 
2007; 13(12): 503-11. 
[17] Vaseghi M, Shivkumar K. The role of the autonomic nervous sys-
tem in sudden cardiac death. Prog Cardiovasc Dis 2008; 50(6): 
404-19. 
[18] Mudd JO, Kass DA. Tackling heart failure in the twenty-first cen-
tury. Nature 2008; 451(7181): 919-28. 
[19] Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, 
Minneman KP, et al. International Union of Pharmacology nomen-
clature of adrenoceptors. Pharmacol Rev 1994; 46(2): 121-36.  
[20] Brodde OE. Beta-Adrenoceptors in cardiac disease. Pharmacol 
Ther 1993; 60(3): 405-30. 
[21] Rengo G, Zincarelli C, Femminella GD, Liccardo D, Pagano G, de 
Lucia C, et al. Myocardial  (2) -adrenoceptor gene delivery pro-
motes coordinated cardiac adaptive remodelling and angiogenesis 
in heart failure. Br J Pharmacol 2012; 166(8): 2348-61. 
[22] Cannavo A, Liccardo D, Lymperopoulos A, Gambino G, D'Amico 
ML, Rengo F, et al.  Adrenergic receptor kinase C-terminal pep-
tide gene-therapy improves 2-adrenergic receptor-dependent 
neoangiogenesis after hindlimb ischemia. J Pharmacol Exp Ther 
2016; 356(2): 503-13. 
[23] Skeberdis VA, Gendviliene V, Zablockaite D, Treinys R, Macian-
skiene R, Bogdelis A, et al. Beta3-Adrenergic receptor activation 
increases human atrial tissue contractility and stimulates the L-type 
Ca2+ current. J Clin Invest 2008; 118(9): 3219-27. 
[24] Rengo G. The adrenergic system in cardiovascular pathophysiol-
ogy: A translational science point of view. Front Physiol 2014; 5: 
356. 
[25] Chalermpalanupap T, Kinkead B, Hu WT, Kummer MP, Hammer-
schmidt T, Heneka MT, et al. Targeting norepinephrine in mild 
cognitive impairment and Alzheimer's disease. Alzheimers Res 
Ther 2013; 5(2): 21. 
[26] Gannon M, Che P, Chen Y, Jiao K, Roberson ED, Wang Q. 
Noradrenergic dysfunction in Alzheimer's disease. Front Neurosci 
2015; 9: 220. 
[27] Femminella GD, Rengo G, Pagano G, de Lucia C, Komici K, Parisi 
V, et al. -Adrenergic receptors and G protein-coupled receptor 
kinase-2 in Alzheimer's disease: A new paradigm for prognosis and 
therapy? J Alzheimer’s Dis 2013; 34(2): 341-7.  
[28] Doze VA, Papay RS, Goldenstein BL, Gupta MK, Collette KM, 
Nelson BW, et al. Long-term 1A-adrenergic receptor stimulation 
improves synaptic plasticity, cognitive function, mood, and longev-
ity. Mol Pharmacol 2011; 80(4): 747-58. 
[29] Torkaman-Boutorabi A, Danyali F, Oryan S, Ebrahimi-Ghiri M, 
Zarrindast MR. Hippocampal alpha adrenoceptors involve in the 
effect of histamine on spatial learning. Physiol Behav 2014; 
129:17-24. 
[30] Nalepa I, Kreiner G, Bielawski A, Rafa-Zabocka K, Roman A. A1-
Adrenergic receptor subtypes in the central nervous system: In-
sights from genetically engineered mouse models. Pharmacol Rep 
2013; 65(6): 1489-97. 
[31] Veyrac A, Nguyen V, Marien M, Didier A, Jourdan F. Noradrener-
gic control of odor recognition in a nonassociative olfactory learn-
ing task in the mouse. Learn Mem 2007; 14(12): 847-54. 
[32] Arnsten AF, Cai JX, Goldman-Rakic Ps. The alpha-2 adrenergic 
agonist guanfacine improves memory in aged monkeys without 
sedative or hypotensive side effects: Evidence for alpha-2 receptor 
subtypes. J Neurosci 1988; 8(11): 4287-98. 
[33] Franowicz JS, Kessler LE, Borja CM, Kobilka BK, Limbird LE, 
Arnsten AF. Mutation of the alpha2A-adrenoceptor impairs work-
ing memory performance and annuls cognitive enhancement by 
guanfacine. J Neurosci 2002; 22(19): 8771-7. 
[34] Gelinas JN, Tenorio G, Lemon N, Abel T, Nguyen PV. Beta-
adrenergic receptor activation during distinct patterns of stimula-
tion critically modulates the PKA-dependence of LTP in the mouse 
hippocampus. Learn Mem 2008; 15(5): 281-9. 
[35] Introini-Collison IB, Miyazaki B, McGaugh JL. Involvement of the 
amygdala in the memory-enhancing effects of clenbuterol. Psycho-
pharmacology (Berl) 1991; 104(4): 541-4. 
Heart Failure and Dementia Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2016, Vol. 10, No. 1    9 
[36] Hecht PM, Will MJ, Schachtman TR, Welby LM, Beversdorf DQ. 
Beta-Adrenergic antagonist effects on a novel cognitive flexibility 
task in rodents. Behav Brain Res 2014; 260: 148-54.  
[37] Schutsky K, Ouyang M, Thomas SA. Xamoterol impairs hippo-
campus-dependent emotional memory retrieval via Gi/o-coupled 
2-adrenergic signaling. Learn Mem 2011; 18(9): 598-604. 
[38] Mirbolooki MR, Constantinescu CC, Pan ML, Mukherjee J. Quan-
titative assessment of brown adipose tissue metabolic activity and 
volume using 18F-FDG PET/CT and 3-adrenergic receptor activa-
tion EJNMMI res 2011; 1(1): 30. 
[39] Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a 
novel gene therapy target in heart failure. J Mol Cell Cardiol 2011; 
50(5): 785-92.  
[40] Rengo G, Lymperopoulos A, Koch WJ. Future g protein-coupled 
receptor targets for treatment of heart failure. Curr Treat Options 
Cardiovasc Med 2009; 11(4): 328-38. 
[41] Lymperopoulos A, Rengo G, Koch WJ. GRK2 inhibition in heart 
failure: Something old, something new. Curr Pharm Des 2012; 
18(2): 186-91. 
[42] Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane 
receptors. Nat Rev Mol Cell Biol 2002; 3(9): 639-50. 
[43] Bathgate-Siryk A, Dabul S, Pandya K, Walklett K, Rengo G, Can-
navo A, et al. Negative impact of -arrestin-1 on post-myocardial 
infarction heart failure via cardiac and adrenal-dependent neuro-
hormonal mechanisms. Hypertension 2014; 63(2): 404-12. 
[44] Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, 
Rabinowitz JE, et al. Myocardial adeno-associated virus serotype 
6-betaARKct gene therapy improves cardiac function and normal-
izes the neurohormonal axis in chronic heart failure. Circulation 
2009; 119(1): 89-98.  
[45] Ciccarelli M, Chuprun JK, Rengo G, Gao E, Wei Z, Peroutka RJ,   
et al. G protein-coupled receptor kinase 2 activity impairs cardiac 
glucose uptake and promotes insulin resistance after myocardial 
ischemia. Circulation 2011; 123(18): 1953-62. 
[46] Raake PW, Vinge LE, Gao E, Boucher M, Rengo G, Chen X, et al. 
G protein-coupled receptor kinase 2 ablation in cardiac myocytes 
before or after myocardial infarction prevents heart failure. Circ 
Res 2008; 103(4): 413-22.  
[47] Femminella GD, Rengo G, Komici K, Iacotucci P, Petraglia L, 
Pagano G, et al. Autonomic dysfunction in Alzheimer's disease: 
Tools for assessment and review of the literature. J Alzheimer’s 
Dis 2014; 42(2): 369-77.  
[48] De Jong MJ, Randall DC. Heart rate variability analysis in the 
assessment of autonomic function in heart failure. J Cardiovasc 
Nurs 2005; 20(3): 186-95. 
[49] Lefrandt JD, Smit AJ, Zeebregts CJ, Gans RO, Hoogenberg KH. 
Autonomic dysfunction in diabetes: A consequence of cardiovascu-
lar damage. Curr Diabetes Rev 2010; 6(6): 348-58. 
[50] Meel-van den Abeelen AS, Lagro J, Gommer ED, Reulen JP, 
Claassen JA. Baroreflex function is reduced in Alzheimer's disease: 
A candidate biomarker? Neurobiol Aging 2013; 34(4): 1170-6. 
[51] Kenny RA, Kalaria R, Ballard C. Neurocardiovascular instability in 
cognitive impairment and dementia. Ann N Y Acad Sci 2002; 977: 
183-95. 
[52] Paolillo S, Rengo G, Pagano G, Pellegrino T, Savarese G, Fem-
minella GD, et al. Impact of diabetes on cardiac sympathetic inner-
vation in patients with heart failure: A 123I meta-
iodobenzylguanidine (123I MIBG) scintigraphic study. Diabetes 
Care 2013; 36(8): 2395-401.  
[53] Spiegel J. Diagnostic and pathophysiological impact of myocardial 
MIBG scintigraphy in parkinson's disease. Parkinsons Dis 2010; 
2010: 295346. 
[54] Corbi G, Conti V, Russomanno G, Rengo G, Vitulli P, Ciccarelli 
AL, et al. Is physical activity able to modify oxidative damage in 
cardiovascular aging? Oxid Med Cell Longev 2012; 2012: 728547. 
[55] Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, Koch 
WJ. An adrenal beta-arrestin 1-mediated signaling pathway under-
lies angiotensin II-induced aldosterone production in vitro and      
in vivo. Proc Natl Acad Sci USA 2009; 106(14): 5825-30. 
[56] Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Koch WJ. Adre-
nal beta-arrestin 1 inhibition in vivo attenuates post-myocardial in-
farction progression to heart failure and adverse remodeling via re-
duction of circulating aldosterone levels. J Am Coll Cardiol 2011; 
57(3): 356-65. 
[57] Cannavo A, Liccardo D, Eguchi A, Elliott KJ, Traynham CJ, Ibetti 
J, et al. Myocardial pathology induced by aldosterone is dependent 
on non-canonical activities of G protein-coupled receptor kinases. 
Nat Commun 2016; 7: 10877. 
[58] Rengo G, Pagano G, Parisi V, Femminella GD, de Lucia C, Lic-
cardo D, et al. Changes of plasma norepinephrine and serum N-
terminal pro-brain natriuretic peptide after exercise training predict 
survival in patients with heart failure. Int J Cardiol 2014; 171(3): 
384-9. 
[59] Koch, W.J., Lymperopoulos, A. Adrenal grk2 activity as a thera-
peutic target for heart failure. US20100048479 (2010). 
[60] Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ. 
Adrenal GRK2 upregulation mediates sympathetic overdrive in 
heart failure. Nat Med 2007; 13(3): 315-23. 
[61] Lymperopoulos A, Rengo G, Zincarelli C, Soltys S, Koch WJ. 
Modulation of adrenal catecholamine secretion by in vivo gene 
transfer and manipulation of G protein-coupled receptor kinase-2 
activity. Mol Ther 2008; 16(2): 302-7.  
[62] Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW 2nd, Koch 
WJ. Reduction of sympathetic activity via adrenal-targeted GRK2 
gene deletion attenuates heart failure progression and improves 
cardiac function after myocardial infarction. J Biol Chem 2010; 
285(21): 16378-86. 
[63] Rengo G, Leosco D, Zincarelli C, Marchese M, Corbi G, Liccardo 
D, et al. Adrenal GRK2 lowering is an underlying mechanism for 
the beneficial sympathetic effects of exercise training in heart fail-
ure. Am J Physiol Heart Circ Physiol 2010; 298(6): H2032-8.  
[64] Femminella GD, de Lucia C, Iacotucci P, Formisano R, Petraglia 
L, Allocca E, et al. Neuro-hormonal effects of physical activity in 
the elderly. Front Physiol 2013; 4: 378.  
[65] Rengo G, Perrone-Filardi P, Femminella GD, Liccardo D, Zin-
carelli C, de Lucia C, et al. Targeting the -adrenergic receptor sys-
tem through G-protein-coupled receptor kinase 2: a new paradigm 
for therapy and prognostic evaluation in heart failure: from bench 
to bedside. Circ Heart Fail 2012; 5(3): 385-91.  
[66] Cannavo A, Rengo G, Liccardo D, Pironti G, Scimia MC, Scudiero 
L, et al. Prothymosin alpha protects cardiomyocytes against ische-
mia-induced apoptosis via preservation of Akt activation. Apopto-
sis 2013; 18(10): 1252-61.  
[67] Rinaldi B, Corbi G, Boccuti S, Filippelli W, Rengo G, Leosco D,  
et al. Exercise training affects age-induced changes in SOD and 
heat shock protein expression in rat heart. Exp Gerontol 2006; 
41(8): 764-70. 
[68] Zincarelli C, Soltys S, Rengo G, Koch WJ, Rabinowitz JE. Com-
parative cardiac gene delivery of adeno-associated virus serotypes 
1-9 reveals that AAV6 mediates the most efficient transduction in 
mouse heart. Clin Transl Sci 2010; 3(3): 81-9. 
[69] Koch, W.J., Lefkowitz, R.J., Milano, C.A., Rockman, H.A. Use of 
exogenous -adrenergic receptor and -adrenergic receptor kinase 
gene constructs to enhance myocardial function. US7060871 
(2006). 
[70] Rengo G, Zincarelli C, Femminella GD, Liccardo D, Pagano G, de 
Lucia C, et al. Myocardial (2)-adrenoceptor gene delivery pro-
motes coordinated cardiac adaptive remodelling and angiogenesis 
in heart failure. Br J Pharmacol 2012; 166(8): 2348-61.  
[71] Salazar NC, Vallejos X, Siryk A, Rengo G, Cannavo A, Liccardo 
D, et al. GRK2 blockade with ARKct is essential for cardiac 2-
adrenergic receptor signaling towards increased contractility. Cell 
Commun Signal 2013; 11: 64.  
[72] Cannavo A, Rengo G, Liccardo D, Pagano G, Zincarelli C, De 
Angelis MC, et al. 1-Adrenergic receptor and sphingosine-1-
phosphate receptor 1 (S1PR1) reciprocal downregulation influences 
cardiac hypertrophic response and progression to heart failure: Pro-
tective role of S1PR1 cardiac gene therapy. Circulation 2013; 
128(15): 1612-22. 
[73] Leosco D, Rengo G, Iaccarino G, Golino L, Marchese M, Fortu-
nato F, et al. Exercise promotes angiogenesis and improves beta-
adrenergic receptor signalling in the post-ischaemic failing rat 
heart. Cardiovasc Res 2008; 78(2): 385-94.  
[74] Koch, W.J., Iaccarino, G. Biomarker for heart failure. 
WO2006052857 (2006). 
[75] Iaccarino G, Barbato E, Cipolletta E, De Amicis V, Margulies KB, 
Leosco D, et al. Elevated myocardial and lymphocyte GRK2 ex-
pression and activity in human heart failure. Eur Heart J 2005; 
26(17): 1752-8. 
[76] Rengo G, Pagano G, Perrone-Filardi P, Femminella GD, Parisi V, 
Cannavo A, et al. Prognostic value of lymphocyte g protein-
coupled receptor kinase-2 protein levels in patients with heart fail-
10    Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2016, Vol. 10, No. 1 Femminella et al. 
ure. Circ Res 2016; CIRCRESAHA.115.308207. [Epub ahead of 
print] PubMed PMID: 26884616. 
[77] Rengo G, Galasso G, Femminella GD, Parisi V, Zincarelli C, Pa-
gano G, et al. Reduction of lymphocyte G protein-coupled receptor 
kinase-2 (GRK2) after exercise training predicts survival in patients 
with heart failure. Eur J Prev Cardiol 2014; 21(1): 4-11.  
[78] Rengo G, Pagano G, Paolillo S, de Lucia C, Femminella GD, Lic-
cardo D, et al. Impact of diabetes mellitus on lymphocyte GRK2 
protein levels in patients with heart failure. Eur J Clin Invest 2015; 
45(2): 187-95. 
[79] Rengo G, Cannavo A, Liccardo D, Zincarelli C, de Lucia C, Pa-
gano G, et al. Vascular endothelial growth factor blockade prevents 
the beneficial effects of -blocker therapy on cardiac function, an-
giogenesis, and remodeling in heart failure. Circ Heart Fail 2013; 
6(6): 1259-67. 
[80] Leosco D, Rengo G, Iaccarino G, Filippelli A, Lymperopoulos A, 
Zincarelli C, et al. Exercise training and beta-blocker treatment 
ameliorate age-dependent impairment of beta-adrenergic receptor 
signaling and enhance cardiac responsiveness to adrenergic stimu-
lation. Am J Physiol Heart Circ Physiol 2007; 293(3): H1596-603. 
[81] Rengo G, Lymperopoulos A, Zincarelli C, Femminella GD, Lic-
cardo D, Pagano G, et al. Blockade of -adrenoceptors restores the 
GRK2-mediated adrenal  (2)-adrenoceptor-catecholamine produc-
tion axis in heart failure. Br J Pharmacol 2012; 166(8): 2430-40. 
[82] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR 
Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's 
disease: Recommendations from the national institute on aging-
Alzheimer’s association workgroups on diagnostic guidelines for 
Alzheimer's disease. Alzheimer’s Dement 2011; 7(3): 263-9. 
[83] Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Sal-
vado O, et al. Amyloid  deposition, neurodegeneration, and cogni-
tive decline in sporadic Alzheimer's disease: A prospective cohort 
study. Lancet Neurol 2013; 12(4): 357-67. 
[84] Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, 
Feinstein D, et al. Neuroinflammation in Alzheimer's disease. Lan-
cet Neurol 2015; 14(4): 388-405. 
[85] Dickstein DL, Walsh J, Brautigam H, Stockton SD Jr, Gandy S, 
Hof PR. Role of vascular risk factors and vascular dysfunction in 
Alzheimer's disease. Mt Sinai J Med 2010; 77(1): 82-102. 
[86] Purnell C, Gao S, Callahan CM, Hendrie HC. Cardiovascular risk 
factors and incident Alzheimer disease: A systematic review of the 
literature. Alzheimer Dis Assoc Disord 2009; 23(1): 1-10. 
[87] Yu JT, Tan L, Hardy J. Apolipoprotein E in Alzheimer's disease: 
An update. Annu Rev Neurosci 2014; 37: 79-100. 
[88] Femminella GD, Ferrara N, Rengo G. The emerging role of mi-
croRNAs in Alzheimer's disease. Front Physiol 2015; 6: 40. 
[89] Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-
development pipeline: few candidates, frequent failures. Alzheim-
ers Res Ther 2014; 6(4): 37. 
[90] Femminella GD, Edison P. Evaluation of neuroprotective effect of 
glucagon-like peptide 1 analogs using neuroimaging. Alzheimer’s 
Dement 2014; 10(1 Suppl): S55-6. 
[91] Klunk, W.E., Mathis, C.A. Jr., Wang, Y. Thioflavin derivatives for 
use in the antemortem diagnosis of Alzheimer’s disease and in vivo 
imaging and prevention of amyloid deposition. US7351401 (2008). 
[92] Efange, S.M., Parsons, S.M. Radiopharmaceutical agents for the 
detection of Alzheimer’s disease. US5721243 (1998). 
[93] Roses, A.D., Strittmatter, W.J., Salvesen, G.S., Enghild, J., 
Schmechel, D. Methods of detecting Alzheimer’s disease. 
WO1994009155 (1994). 
[94] Schellenberg, G.D., Bird, T.D., Wijsman, E.M. Chromosome 14 
and familial Alzheimer’s disease genetic markers and assays. 
US5449604 (1995). 
[95] Alkon, D.L., Favit, A., Grimaldi, M. Diagnostic tests for Alz-
heimer’s disease. WO1999058981 (1999). 
[96] Nixon, R.A., Cataldo, A.M., Kao, B.H., Mathews, P.M. Use of 
presenilin-1 for diagnosis of Alzheimer’s disease. US5985581 
(1999). 
[97] Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes 
in beta-adrenergic receptor subtypes in Alzheimer-type dementia. J 
Neurochem 1987; 48(4): 1215-21. 
[98] Lee RKK, Araki W, Wurtman RJ. Stimulation of amyloid precur-
sor protein synthesis by adrenergic receptors coupled 
tocAMPformation. Proc Natl Acad Sci USA1997; 94(10): 5422-
5426. 
[99] Wang D, Yuen EY, Zhou Y, Yan Z, Xiang YK. Amyloid beta 
peptide-(1-42) induces internalization and degradation of beta2 
adrenergic receptors in prefrontal cortical neurons. J Biol Chem 
2011; 286(36): 31852-63. 
[100] Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is 
greater in the locus coeruleus than nucleus basalis and substantia 
nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003; 
60(3): 337-41.  
[101] Haglund M, Sjobeck M, Englund E. Locus ceruleus degeneration is 
ubiquitous in Alzheimer’s disease: Possible implications for diag-
nosis and treatment. Neuropathology 2006; 26(6): 528-32. 
[102] Matthews KL, Chen CP, Esiri MM, Keene J, Minger SL, Francis 
PT. Noradrenergic changes, aggressive behavior, and cognition in 
patients with dementia. Biol Psychiatry 2002; 51(5): 407-16. 
[103] Raskind MA, Peskind ER, Holmes C, Goldstein DS. Patterns of 
cerebrospinal fluid catechols support increased central noradrener-
gic responsiveness in aging and Alzheimer’s disease. Biol Psychia-
try 1999; 46(6): 756-65. 
[104] Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind 
MA. Compensatory changes in the noradrenergic nervous system 
in the locus ceruleus and hippocampus of postmortem subjects with 
Alzheimer’s disease and dementia with Lewy bodies. J Neurosci 
2006; 26(2): 467-78. 
[105] Lee RK, Araki W, Wurtman RJ. Stimulation of amyloid precursor 
protein synthesis by adrenergic receptors coupled to cAMP forma-
tion. Proc Natl Acad Sci USA 1997; 94(10): 5422-6. 
[106] Igbavboa U, Johnson-Anuna LN, Rossello X, Butterick TA, Sun 
GY, Wood WG. Amyloid beta-protein1-42 increases cAMP and 
apolipoprotein E levels which are inhibited by beta1 and beta2-
adrenergic receptor antagonists in mouse primary astrocytes. Neu-
roscience 2006; 142(3): 655-60. 
[107] Ni Y, Zhao X, Bao G, Zou L, Teng L, Wang Z, et al. Activation of 
beta2-adrenergic receptor stimulates gamma-secretase activity and 
accelerates amyloid plaque formation. Nat Med 2006; 12(12):1390-
6. 
[108] Leosco D, Fortunato F, Rengo G, Iaccarino G, Sanzari E, Golino L, 
et al. Lymphocyte G-protein-coupled receptor kinase-2 is upregu-
lated in patients with Alzheimer’s disease. Neurosci Lett 2007; 
415(3): 279-82. 
[109] Testa G, Cacciatore F, Galizia G, Della-Morte D, Mazzella F, 
Langellotto A, et al. Waist circumference but not body mass index 
predicts long-term mortality in elderly subjects with chronic heart 
failure. J Am Geriatr Soc 2010; 58(8): 1433-40. 
[110] Testa G, Cacciatore F, Galizia G, Della-Morte D, Mazzella F, 
Gargiulo G, et al. Depressive symptoms predict mortality in elderly 
subjects with chronic heart failure. Eur J Clin Invest 2011; 41(12): 
1310-7.  
[111] Cermakova P, Eriksdotter M, Lund LH, Winblad B, Religa P, 
Religa D. Heart failure and Alzheimer's disease. J Intern Med 2015; 
277(4): 406-25. 
[112] Prins ND, van der Flier WM, Brashear HR, Knol DL, van de Pol 
LA, Barkhof F, et al. Predictors of progression from mild cognitive 
impairment to dementia in the placebo-arm of a clinical trial popu-
lation. J Alzheimer’s Dis 2013; 36(1): 79-85.  
[113] Roher AE, Debbins JP, Malek-Ahmadi M, Chen K, Pipe JG, Maze 
S, et al. Cerebral blood flow in Alzheimer's disease. Vasc Health 
Risk Manag 2012; 8: 599-61. 
[114] Kim MS, Kim JJ. Heart and brain interconnection - clinical impli-
cations of changes in brain function during heart failure. Circ J 
2015; 79(5): 942-7.  
[115] Nguyen, P., Chow, K., Heidelbaugh, T. Selective subtype alpha 2 
adrenergic agents and methods for use thereof. EP2319511 (2012).  
[116] Fang, W.K., Nguyen, P., Chow, K., Heidelbaugh, T., Gomez, D.G, 
Garst, M., Sinha, S. Methods of treating alpha adrenergic mediated 
conditions. EP2377534 (2011).  
[117] Zimmer, D.P., Currie, M.G, Fretzen, A., Milne, T. Methods and 
compositions for the treatment of heart failure and other disorders. 
EP2650303 (2013). 
[118] Liggett, S., Small, K. Polymorphismes et haplotypes du gene du 
recepteur adrenergique alpha 2c. WO2006004939 (2006). 
[119] Salehi, A., Mobley, W.C., Vallette, J. Method of improving cogni-
tive functions in individuals with down syndrome and/or Alz-
heimer’s disease. WO2010132128 (2010).  
[120] Pearse, L.T., Power, R. Use of selenium compounds, especially 
selenium yeasts for altering cognitive function. EP1779858 (2013). 
